Ann: SIRFLOX ASCO Abstract Released, page-16

Hey slashj

This is where the crux of the matter lies .

Overall PFS includes any tumour getting bigger equals fail.
SRX is liver targetted. And maybe elsewhere someday but at the moment this is monumentous news

It works and backs the wealth of smaller trials that show this.
Its very strongly statistically significant
Its had complete response in 6% of patients.
Dose sales are the highest they have ever been.
Patients have an 8 month PFS extension ( liver) in a well conducted randomised multi centre trial

Overall PFS was always going to be hard as a primary endpoint but apparently thats what FDA wanted and oncologist look for. Its a surrogate for OS , and worked out earlier in research but potentially misleading when assessing an organ specific treatment.

There is still the possibility of first line ( await OS) particularly in liver only/dominant metastatic colon ca
There is still the potential huge market of primary HCC ) plus other metastatic disorders

And this in all based on a SINGLE dose of sir spheres with minimal systemic effects compared to a prolonged course of chemotherapy.

the goal of Sirtex to turn metastatic carcinoma of the liver into a controllable disease...